Javier San Martin
Vermögen: 151 562 $ am 31.05.2026
Vermögen: 151 562 $ am 31.05.2026
Zurzeit ist Javier San Martin Chief Medical Officer bei Arrowhead Pharmaceuticals, Inc. Zuvor war er Executive Director-Bone Therapeutic Area bei Amgen, Inc. und Principal bei Eli Lilly & Co. sowie Senior VP-Global Clinical Development bei Ultragenyx Pharmaceutical, Inc. und Senior Vice President-Clinical Development bei Alder Biopharmaceuticals, Inc. Er erhielt einen Doktortitel von der Universidad de Buenos Aires.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LEONABIO, INC. 0,17 % | 01.05.2026 | 15.887 ( 0,17 % ) | 151 562 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LEONABIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 15.04.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.11.2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 7 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drugs to treat intractable diseases | Health Technology |
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
LeonaBio, Inc.
LeonaBio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
University of Buenos Aires School of Medicine
University of Buenos Aires School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen